This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Liberato NL, Marchetti M, Barosi G.Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology 25: 625-633, No. 6, 20 Feb 2007
Kurian AW, Newton Thompson R, Gaw AF, Arai S, Ortiz R, Garber AM.A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. Journal of Clinical Oncology 25: 634-641, No. 6, 20 Feb 2007
Hillner BE, Smith TJ.Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? Journal of Clinical Oncology 25: 611-613, No. 6, 20 Feb 2007
Rights and permissions
About this article
Cite this article
Trastuzumab cost effective in HER2-positive breast cancer. Pharmacoecon. Outcomes News 527, 4 (2007). https://doi.org/10.1007/BF03309404
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03309404